Clinical trial · Interventional
Study of BMS-986012 in Subjects With Small Cell Lung Caner
A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer
NCT02949895CI-TRIAL-00039998completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Dose Escalation Dose 1
- description
- BMS-986012 Dose Escalation Dose 1
- interventionNames
- Drug: BMS-986012
- type
- EXPERIMENTAL
- label
- Dose Escalation Dose 2
- description
- BMS-986012 Dose Escalation Dose 2
- interventionNames
- Drug: BMS-986012
- type
- EXPERIMENTAL
- label
- Chemotherapy Combination
- description
- BMS-986012 + Cisplatin + Etoposide
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com * Histological or cytological confirmed small cell lung cancer (SCLC) * Eastern Cooperative Oncology Group Performance Status 0-1 * at least one measurable lesion that is not amenable to resection. * Adequate organ function Exclusion Criteria: * Symptomatic central nervous system (CNS) metastases * Grade ≥ 2 peripheral neuropathy * Uncontrolled or significant cardiac disease * Active or chronic infection with Human Immunodeficiency Virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.